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ABBREVIATIONS
Ang Angiopoietin
ATP Adenosine triphosphate
Bmx Bone marrow tyrosine kinase gene in chromosome X
Btk Bruton’s tyrosine kinase
E8.5 Embryonic day (8.5)
EC Endothelial cell
EPC Endothelial progenitor cell
Etk Epithelial and endothelial tyrosine kinase (Bmx)
FGF Fibroblast growth factor
HIF Hypoxia inducible factor
HPC Hematopoietic progenitor cell
HSPG Heparan sulfate proteoglycan
Itk Interleukin-2-inducible T cell kinase
KO Knockout
mRNA Messenger ribonucleic acid
NRTK Non-receptor tyrosine kinase
P2 Postnatal day (2)
PC Pericyte
PDGF Platelet-derived growth factor
PDGFR Platelet-derived growth factor receptor
PI3K Phosphatidylinositol 3-kinase
PlGF Placenta growth factor
PTKs Protein tyrosine kinases
RA Rheumatoid arthritis
RTK Receptor tyrosine kinase
SMC Smooth muscle cell
STAT Signal transducer and activator of transcription
sVEGFR-1 Soluble VEGFR-1
Tec Tyrosine kinase expressed in hepatocellular carcinoma
TG Transgenic
TGF-a Transforming growth factor alpha
Tie Tyrosine kinase with Ig and EGF homology domains
TNF-a Tumor necrosis factor alpha
Txk T cell X chromosome kinase
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
WT Wildtype
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ABSTRACT
Neoplastic cells are characterized by distinct alterations in the genome that are associated with
characteristic changes in cell physiology: self-sufficiency in growth signals, insensitivity to anti-
growth signals, resistance to programmed cell death, limitless replicative ability, the ability to
invade tissue and metastasize and the capability of inducing sustained angiogenesis through the
secretion of angiogenic molecules. Vascular Endothelial Growth Factor (VEGF) is the principal
angiogenic molecule involved in both physiologic and pathologic angiogenesis. VEGF belongs to
the VEGF gene family comprising of VEGF, VEGF-B, VEGF-C, VEGF-D and Placenta Growth
Factor (PlGF). VEGF gene family members bind and phosphorylate receptor tyrosine kinases on
endothelial cells. This signal is relayed to the cell nucleus through intracellular signal mediators
such as the Bmx tyrosine kinase leading to changes in gene expression.
In this study, newly cloned members of the VEGF family were analysed. Human VEGF-B and
VEGF-C genes were localized to the chromosomal loci 11q13 and 4q34, respectively. VEGF-B and
VEGF-C were not significantly amplified in the breast cancer cell lines studied and they did not
localize to known cancer amplicons in the human genome. The mRNA regulation of VEGF-B and
VEGF-C by serum, growth factors, oncoproteins and hypoxia was analysed and found to differ
significantly from the VEGF mRNA regulation. For example, unlike VEGF, neither VEGF-B nor
VEGF-C was upregulated by hypoxia. Serum, growth factors and oncoproteins upregulated VEGF-
C mRNA, whereas VEGF-B mRNA was not regulated by any of these stimuli. The receptor for
VEGF-C and VEGF-D, VEGFR-3, was found to be expressed in lymphatic endothelial cells during
the transient in-growth of lymphatic vessels into the wound bed during dermal wound healing.
Wound healing angiogenesis and lymphangiogenesis were concurrent processes with different
kinetics. VEGFR-3 was upregulated on blood vascular endothelium during chronic inflammation
and VEGF-C was strongly expressed in the inflamed synovial membranes in rheumatoid arthritis.
VEGFR-3 was expressed on lymphatic endothelium and also on the endothelium of synovial
capillaries and venules. These studies indicate that VEGF-C is induced by various proinflammatory
cytokines and growth factors and that VEGF-C and its receptor VEGFR-3 could be involved in the
pathogenesis of inflammatory processes.
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Bmx, a tyrosine kinase involved in VEGF signaling and expressed in arterial endothelium, was not
upregulated in angiogenic vessels during angiogenesis. Bmx was however expressed in migrating
epithelial keratinocytes during the re-epithelialization of dermal wounds. Epidermal overexpression
of Bmx in transgenic mice stimulated keratinocyte proliferation and accelerated dermal wound
healing. The Bmx transgene also induced dermal inflammation and angiogenesis with strong
changes in the epidermal gene expression profiles. These results suggest that Bmx expression, that
has been detected in prostate carcinomas, could be associated with important aspects of tumor
progression.
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REVIEW OF THE LITERATURE
Vascular development
Vasculogenesis and angiogenesis
During human embryogenesis, the vascular system appears during the third week of development
when the nutritional requirements of the embryo can no longer be met solely by diffusion 1. The
angioblasts, i.e. the endothelial progenitor cells (EPC) and the hematopoietic progenitor cells
(HPC) are thought to originate from a common mesoderm-derived progenitor cell, the
hemangioblast. Hemangioblasts aggregate to form primitive blood islands in the yolk sac in
response to growth factor signals 2. The cells in the center of these blood islands become
hematopoietic progenitor cells while the outer cells become angioblasts 2. Angioblasts proliferate,
differentiate and organize to form a primitive vascular plexus composed of endothelial tubes.
VEGF and its receptors represent the first endothelial-cell specific signaling pathway during
development 3. The primitive vascular system is remodeled into a mature vascular network through
a process termed angiogenesis 4. During angiogenesis, new vessels are formed from pre-existing
ones through sprouting or non-sprouting mechanisms such as splitting or bridging 3. The novel
vascular sprouts form capillary loops that develop into capillary networks. Excess vessels are
pruned and vessels may fuse together. Endothelial cells (EC) acquire a basement membrane,
vessels become covered by pericytes (PC) and smooth muscle cells (SMC) and undergo arterial-
venous differentiation 5. The EC at the site of angiogenesis may also be derived through
recruitment of circulating EPC derived from the bone marrow 6-8. Cells capable of differentiating
into EC have also been discovered in skeletal muscle 9. Angiogenesis is tightly controlled in the
adult by a balance between angiogenic and anti-angiogenic stimuli, occurring only in special
circumstances such as during the female reproductive cycle, during placental development or
during wound healing 10.
Arteriogenesis
Arteriogenesis is the development of functional collateral vessels from pre-existing small arterioles
in occlusive arterial disease 3,11. Although arteriogenesis is often accompanied by angiogenesis and
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vice versa, arteriogenesis differs significantly from angiogenesis at the cellular and molecular level.
Angiogenesis is rarely capable of providing functional blood perfusion to acutely ischemic tissues
but arteriogenesis results in the development of true collateral arteries capable of providing a 10- to
20-fold increase in tissue blood flow. Arteriogenesis is initiated by an increase in fluid shear stress,
which activates the vascular endothelium. The activated endothelium begins to express monocyte
chemotactic protein and cell adhesion molecules involved in the attachment and trans-endothelial
migration of monocytes 12. Monocytes are recruited to the perivascular space where they release
proteases, growth factors and cytokines involved in the recruitment of EC and SMC to the new
vessel. Arteriogenesis then proceeds with the remodeling phase. A new elastic lamina is
synthesized by the SMC, the vessel wall thickens and the vessels increase in tortuosity.
Hematopoiesis
During early development, hematopoiesis, the development of blood cells, occurs in tight proximity
to the development of the vascular system. Hematopoietic cells appear first in the extraembryonic
yolk sac 13. These inner cells of blood islands are mostly nucleated red blood cells expressing fetal
hemoglobin. In humans, primitive hematopoiesis is only transient and as it declines, the so-called
definitive hematopoiesis begins in the embryo proper in the fetal liver. Since different animal
models have yielded contradicting data, the origin of definitive hematopoietic stem cells (HSC) is
unclear 14. The intraembryonic HSC of humans are thought to be derived primarily from clusters of
hematopoietic cells attached to the ventral wall of the dorsal aorta in the para-aortic
splanchnopleura 14-16. EC and definitive HSC have common surface markers, vascular endothelial
growth factor receptor -1 (VEGFR-1), VEGFR-2 and Tie-2 among others 17. Definitive
hematopoiesis occurs from mid-gestation onwards also in the spleen, moving to the bone marrow in
the adult 1. In the adult, hematopoiesis occurs solely in the bone marrow, except for certain
pathologic conditions where extramedullary hematopoiesis may be present.
Lymphangiogenesis
The lymphatic system begins in the interstitium as blind-ended lymphatic capillaries that collect
interstitial fluid, immune cells, proteins, other macromolecules and debris and in the gut, also
lipids. Lymphatic capillaries are very permeable, thin-walled vessels with large inter-endothelial
pores lacking a continuous basal lamina and pericytes 18-20. The lymphatic capillaries feed into
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lymph nodes where antigen presentation and clonal expansion of immune cells takes place. Lymph
continues into larger collecting ducts, the left and right thoracic ducts and finally into the systemic
blood circulation. The development of embryonic lymphatic vessels has been less studied than
vasculogenesis and angiogenesis. In 1902, Sabin proposed that during embryogenesis, the
lymphatic vasculature develops by sprouting lymphangiogenesis from the lymph sacs 21. Recent
data on the expression of early markers of lymphatic endothelium on the endothelium lining the
budding lymphatic sacs in mice have supported Sabin’s theory 22-25. The lymphatic vascular system
in peripheral tissues has been suggested to develop from the fusion of mesenchymal lymphatic
spaces that develop separately from blood vessels 26. In a quail-chick chimera model, mesodermal
lymphatic progenitor cells may participate in lymphatic vessel development 27-29. Lymphatic EC are
thought to develop from venous EC. This theory has been supported by studies on the ability of the
prospero related homeobox protein-1 (Prox1) to re-program blood vascular EC into lymphatic EC
and also by studies on the differences and similarities in the gene expression profile of lymphatic
and blood vascular EC 30-33. Studies on the VEGF-C knockout mice have offered insight into the
interplay between VEGF-C and VEGFR-3 in the development of the lymphatic vasculature 34.
Lymphangiogenesis in the adult has not been extensively studied and the cell-cell communication
between angiogenic and lymphangiogenic EC in vivo is unclear.
Vascular endothelial growth factor family
Figure 1. A simplified scheme of ligand-receptor binding in the VEGF gene family in humans.
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VEGF
In mammals, the Vascular Endothelial Growth Factor (VEGF) gene family comprises five dimeric
glycoproteins able to bind and activate VEGF receptor tyrosine kinases (VEGFRs): VEGF, VEGF-
B, VEGF-C, VEGF-D and the placenta growth factor (PlGF). VEGF binds VEGFR-1 and VEGFR-
2. VEGF is secreted by a broad range of cells including PC/SMC, fibroblasts and hematopoietic
cells. VEGF induces the proliferation, sprouting, migration and tubule formation of EC 35. VEGF is
also a potent survival factor for angiogenic EC during physiological and tumor angiogenesis and
induces the expression of anti-apoptotic proteins in the EC 36-38. VEGF was originally described as a
permeability factor 39. VEGF induces potent changes in the permeability of EC through formation
of transcellular gaps, vesico-vascular organelles, vacuoles and fenestrations 40. VEGF causes
vasodilatation through the induction of the endothelial nitric oxide (NO) synthase and the
subsequent increase of NO production 41-43. Although VEGF acts mostly on EC it has been shown
to also bind VEGF receptors on HSC, monocytes, osteoblasts and neurons 44-47. In these cells VEGF
induces for example HSC mobilization from the bone marrow, monocyte chemoattraction,
osteoblast-mediated bone formation and neuronal protection and angiogenesis 48-50. VEGF
stimulates inflammatory cell recruitment and also the expression of proteases implicated in the
degradation of the basal lamina in the early stages of angiogenesis 51-53. VEGF is strongly induced
by hypoxia due to hypoxia-inducible factor (HIF) regulated elements of the VEGF gene 54,55. Many
cytokines including platelet-derived growth factor, epidermal growth factor, transforming growth
factors and basic fibroblast growth factor induce VEGF expression and may also regulate VEGF
mRNA stability 56,57. Six forms of VEGF are produced through alternative splicing: VEGF121,
VEGF145, VEGF165, VEGF183, VEGF189 and VEGF206 50. VEGF121, VEGF165 and VEGF189 are the
major forms secreted by most cell types 58. VEGF121 diffuses freely, while in general approximately
half of the secreted VEGF165 binds to cell surface heparan sulfate proteoglycans (HSPGs). VEGF189
remains almost completely sequestered by HSPGs in the extracellular matrix and the HSPGs
provide a reservoir of VEGF isoforms that may be released by proteolytic enzymes 59-61. VEGF145
and VEGF206 are expressed primarily in the placenta and VEGF183 is expressed in the retina 62-64.
Recently, also an inhibitory splice form of VEGF, termed VEGF165b, has been found and it is
downregulated in renal cell carcinoma 65.
VEGF is ubiquitously expressed in embryonic tissues, but expression is stronger at sites of active
vasculogenesis and angiogenesis 66. VEGF is expressed in practically all solid tumors studied and
also in hematological malignancies 50,67. VEGF inhibition in experimental tumors reduces tumor
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growth and correlations have also been found in human cancer patients between VEGF expression
and various parameters such as disease progression and survival 68-70. Transgenic mice
overexpressing VEGF in the skin develop an inflammatory skin condition resembling psoriasis 71.
Overexpression of VEGF in murine skin also accelerates experimental tumor growth 72.
Homozygous VEGF knockout (KO) mice die at E8-E9 from defects in the very early blood island
formation, in EC development, in EC differentiation and in tubule formation (see Table 2) 73. The
levels of VEGF protein during development are crucial since mice lacking even a single VEGF
allele also die at E11-E12, displaying defects in early vascular development 74. The different
biological functions of VEGF isoforms were recently demonstrated by studying isoform-specific
KO mice. Mice expressing only VEGF120 (human VEGF121) die in part soon after birth and those
that survive develop lethal ischemic cardiomyopathy 75. Mice expressing only VEGF188 (human
VEGF189) display impaired arteriolar development and approximately half die at birth 76. Mice
expressing only VEGF164 (human VEGF165) are viable and healthy 76. These studies underline the
importance of VEGF164 (human VEGF165) as the principal effector of VEGF action.
Gene Chromosomal
localization
Splice variants Major protein size Major mRNA transcript
size
VEGF 6p23.1 77 121,145, 165*,
183*, 189*, 206*,
165b
21kDa 3.7kB, 4.5kB
VEGF-B - 167*, 186 21kDa, 30kDa 1.4kB
VEGF-C - - 20-21kDa 2.4kB
VEGF-D Xp22.31 78,79 - 20-21kDa 2.2kB
PlGF 14q24 80,81 131, 152*, 219 38kDa, 30kDa 1.7kB
1.2kB
VEGFR-1 13q12-q13 82 180kDa 7.5kB, 8.0kB
VEGFR-2 4q11-q12 83 230kDa 7.0kB
VEGFR-3 5q33-qter 84 VEGFR-3,
(VEGFR-3 short)
195kDa 4.5kB, 5.8kB
Table 1. VEGF family members and receptors in humans, chromosomal localization, splice
variants, major protein and mRNA transcript sizes. * indicates heparin-binding form. kB = kilobase
(1000 nucleotide bases), kDa = kilodalton (100 daltons).
PlGF
Placenta growth factor (PlGF) was originally discovered in a human placental cDNA library 85.
PlGF binds VEGFR-1 86,87. PlGF is angiogenic and also arteriogenic 88. It induces recruitment and
survival of bone marrow derived VEGFR-1 positive stem cells 89. Alternative splicing leads to three
different forms of human PlGF: PlGF-1 (PlGF131), PlGF-2 (PlGF152) and PlGF-3 (PLGF221) 80. PlGF
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forms homodimers and PlGF/VEGF165 heterodimers 90,91. In mice, PlGF is expressed most
abundantly in the heart and lungs 92,93. In several animal models PlGF induces the formation of
mature, leakage-resistant PC-covered vessels 94,95. PlGF has also been shown to induce dermal
angiogenesis, increase permeability and increase induction of dermal inflammation when
overexpressed in the skin of transgenic mice 96,97. PlGF KO mice are viable but exhibit impaired
pathologic angiogenesis and arteriogenesis (see Table 2) 98-100.
Figure 2. Phylogeny of the VEGF gene family.
VEGF-B
VEGF-B (also called VEGF-related factor/VRF) was discovered independently by two laboratories
101,102. VEGF-B binds VEGFR-1, but its biological function is not known 103. Two different splice
forms of human VEGF-B exist: the predominant form VEGF-B167 that is partly sequestered by
HSPGs and VEGF-B186 104. During development, VEGF-B is expressed most prominently in the
developing myocardium 105. In the adult VEGF-B is expressed in most tissues but expression is
more abundant in the heart and in the skeletal muscle 106. VEGF-B has been shown to regulate
plasminogen activity in EC 103. Two independently generated VEGF-B KO mice were healthy and
had a slightly prolonged PQ-conduction time or slightly reduced myocardial size (Table 2) 107,108.
The VEGF-B KO mice recover slightly less well from experimental transient myocardial ischemia
107.
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VEGF-C
VEGF-C is produced as a single propeptide, the N-terminal and C-terminal ends are proteolytically
processed to generate a protein with high affinity for VEGFR-2 and VEGFR-3 109. VEGF-C
induces mitogenesis and migration of EC 109. VEGF-C is also a survival factor for lymphatic EC 30.
During development, VEGF-C is expressed along with its receptor VEGFR-3 predominantly in
regions where lymphatic vessels develop and also in the developing mesenterium 110. VEGF-C
induces selective lymphangiogenesis in vivo in a chick chorioallantoic membrane assay 20. VEGF-C
overexpression in the skin of transgenic mice induces the development of hyperplastic dermal
lymphatic vessels in vivo with no such effects on blood vasculature 111. Adenovirus mediated gene
transfer of VEGF-C (AdVEGF-C) reduces experimental neointima formation in balloon-neduded
rabbit aorta 112. AdVEGF-C induces growth of functional lymphatic vessels in several different
animal models 113-116. Tumor cells overexpressing VEGF-C induce peritumoral lymphangiogenesis
and tumor cell invasion into lymphatic vessels in animal models 117-121. VEGF-C, the proteolytically
processed form in particular, has also been shown to be angiogenic at high concentrations 122,123.
Studies of cancer patients have shown a positive correlation between VEGF-C expression and
lymphatic invasion and metastasis and patient survival whereas in a small number of studies no
such correlation was found 67. VEGF-C expression is an independent prognostic factor in cervical
cancer and gastric cancer 124,125. VEGF-C KO mice die prenatally from fluid accumulation in tissues
due to lack of development of lymphatic vessels (see Table 2) 34. The endothelial cells commit to
the lymphatic lineage but do not however sprout to form lymphatic vessels. The lymphatic vascular
sprouting is rescued by the lymphangiogenic VEGF-C and VEGF-D but not by the angiogenic
VEGF, indicating specificity for VEGFR-3 34. These results indicate that VEGF-C is a crucial
paracrine growth factor for the development of the lymphatic vasculature. VEGF-C is not however
essential for the development of blood vessels unlike its receptors VEGFR-2 and VEGFR-3.
Heterozygous VEGF-C KO mice also have lymphatic developmental defects indicating that VEGF-
C is essential for the development of the lymphatic vasculature in a concentration dependant
manner 34.
VEGF-D
VEGF-D is the closest relative of VEGF-C 78,126. Like VEGF-C, the human VEGF-D also binds and
activates VEGFR-2 and VEGFR-3 and is mitogenic for EC and angiogenic and lymphangiogenic in
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vivo 127-129. Murine VEGF-D binds only VEGFR-2 indicating a possibly different role for VEGF-D
in mice 130. VEGF-D is processed like VEGF-C in its N-terminal and C-terminal ends 78,131. VEGF-
D is present in most human tissues but it is most abundant in the lung 132. In experimental tumors
VEGF-D increases lymphatic vessel growth and lymphatic metastasis 133. VEGF-D is expressed by
melanoma cells and has been proposed to have a role in tumor angiogenesis and
lymphangiogenesis 134. VEGF-D has been shown to be of prognostic value for lymphatic invasion
and also survival in certain human cancers 67. A VEGF-D KO has not been published.
Gene KO lethality Defects in vascular development
observed in KO
Proposed vascular function
VEGF (-/-) E8-E9
(+/-) E11-E12
Defective blood vessel and blood
island development † 74
Induction of vasculogenesis, angiogenesis
and hematopoiesis
VEGF-B survive No phenotype 108 or slightly smaller
myocardium 107
Unknown
VEGF-C E15.5-E17.5,
no live pups
born
Defective lymphatic vessel sprouting,
edema 34
Induction of lymphatic sprouting,
lymphatic EC survival
PlGF survive Defective pathologic angiogenesis 98 Recruitment of EPC?
VEGFR-1 E8.5 Defective vasculogenesis and
angiogenesis, excess EC progenitors
135,136
VEGF regulation, pathologic angiogenesis,
recruitment and survival EPC?
VEGFR-2 E8.5-E9.5 Defective vasculogenesis, blood island
and hematopoietic cell development 137
Hemangioblast differentiation, proliferation
and migration
VEGFR-3 E9.5-E10.5 Defective angiogenesis, pericardial
effusion 138
BV maturation in development, growth and
survival of LV
PDGF-B P0 Hemorrhaging, microaneurysms,
defective PC recruitment 139
SMC growth and PC recruitment and
survival
PDGFRb P0 Hemorrhaging, microaneurysms,
defective PC recruitment 140
PC maturation, BV stabilization
Ang-1 E12.5 Defective vascular modeling 141 Recruitment of PC, BV stabilization
Ang-2 <P14 Defective postnatal angiogenesis,
lymphatic vessel abnormalities 142
BV stabilization, BV and LV remodeling
Tie-1 E13.5-P0 Defective EC integrity, edema,
hemorrhaging 143
BV stabilization and EC survival, EC-PC
interactions
Tie-2 E9.5-E10.5 Defective vasculogenesis,
angiogenesis, PC recruitment, cardiac
defects 144
BV stabilization and EC survival, EC-PC
interactions
Nrp-1 E12.5-E13.5 Defects in neural vascularization, and
yolk sac vasculature, cardiac defects 145
Axon guidance, VEGF co-receptor, VEGF
regulation in development
Ephrin B2 E11 Defective vascular remodeling and
cardiac defects 146
Establishment of arterial EC identity
EphB4 E10 Defective vascular remodeling and
cardiac defects 147
Establishment of venous EC identity
Table 2. Mouse models of targeted inactivation of genes involved in vasculogenesis and
angiogenesis. EC = endothelial cell, BV = blood vessel, LV = lymphatic vessel, EPC = endothelial
progenitor cell, PC = pericyte, SMC = smooth muscle cell. † see text for details on isoform-specific
KO-studies.
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VEGFR-2
VEGFR-2 is composed of seven extracellular immunoglobulin (Ig) homology domains, a single
transmembrane region and an intracellular tyrosine kinase (TK) domain that is interrupted by a
kinase-insert domain 148,149. VEGFR-2 binds VEGF, VEGF-C and VEGF-D. Although the binding
affinity of VEGF towards VEGFR-2 is lower than that for VEGFR-1, it is thought that most of the
biological effects of VEGF are transduced through VEGFR-2 150,151. Using receptor-specific VEGF
mutants VEGFR-2 has also been shown to be the sole VEGF receptor signaling EC migration,
angiogenesis and vascular permeability 152. In addition to EC, VEGFR-2 is also expressed on
neuronal cells, osteoblasts, pancreatic duct cells, retinal progenitor cells, megakaryocytes and
hematopoietic stem cells 50,153. VEGFR-2 expression is downregulated in the adult blood vascular
EC but VEGFR-2 is upregulated in the endothelium of angiogenic blood vessels 154. VEGFR-2
associates with integrin aVb3 upon binding VEGF and this may be associated with integrin-
dependent migration of EC 155,156. During development VEGFR-2 is expressed by the primitive
endoderm and embryonic angioblasts 73,74,157. VEGFR-2 is also expressed in the blood islands and in
angiogenic vessels 158,159. VEGFR-2 KO mice are embryonic lethal at E8.5-E9.5 from
developmental defects including lack of development of the blood islands, embryonic vasculature
and hematopoietic cells (see Table 2) 137,159.
VEGFR-1
The overall structure of VEGFR-1 is similar to that of VEGFR-2 160. VEGFR-1 binds VEGF,
VEGF-B and PlGF. Upon ligand binding to VEGFR-1, phosphorylation and mitogenic signaling to
EC is much weaker than that of VEGFR-2 161,162. VEGFR-1 may act as a decoy receptor regulating
the bioavailability of VEGF and it may also modulate VEGFR-2-mediated signaling 163. VEGFR-1
forms heterodimers with VEGFR-2 in vivo 164. VEGFR-1 is expressed on EC and also on
osteoblasts, monocyte/macrophages, pericytes, placental trophoblasts, renal mesangial cells and in
some hematopoietic stem cells 50,165. VEGFR-1 activation induces monocyte migration and may
also have an important role in inflammatory angiogenesis 166,167. VEGFR-1 signaling is also
involved in the recruitment and survival of bone marrow derived progenitor cells 89,168. VEGFR-1 is
also expressed along with VEGFR-2 in human testis and myometrium 153. VEGFR-1 expression is
upregulated during angiogenesis and unlike VEGFR-2, hypoxia upregulates VEGFR-1 expression
154,169. Pathologic angiogenesis e.g. during experimental tumor growth is impaired with anti-
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VEGFR-1 antibodies 95. A soluble form of VEGFR-1 (sVEGFR-1, i.e. the extracellular portion of
VEGFR-1) has been described which inhibits VEGF action 170. sVEGFR-1 has been linked to the
development of gestational toxemia and pre-eclampsia 171,172. Women with pre-eclampsia have
elevated circulating sVEGFR-1 levels and decreased circulating PlGF and VEGF 173. The relative
absence of VEGF and PlGF may lead to EC dysfunction in the maternal and placental vasculature.
During development, VEGFR-1 is first expressed in angioblasts and in endothelia although less
strongly than VEGFR-2, VEGFR-1 expression subsides during later embryonic development
135,158,174. VEGFR-1 KO mice die at E8.5 due to disorganization of blood vessels and overgrowth of
EC in the blood vessels with few hemangioblasts being formed (see Table 2) 135,136. Although
VEGFR-1 KO mice do not survive, mice lacking only the intracellular kinase domain are fertile
and normal with impaired pathologic angiogenesis 175,176.
VEGFR-3
VEGFR-3 has only six Ig-homology domains as the fifth Ig-homology domain is proteolytically
cleaved soon after biosynthesis and the resulting polypeptide chains remain linked via a disulfide
bond 177,178. VEGFR-3 binds VEGF-C and VEGF-D 131,179. The VEGF-C/VEGFR-3 pathway is
crucial for the development of the lymphatic vasculature 34. VEGFR-3 is present on all endothelia
during development but in the adult it becomes restricted to lymphatic EC and certain fenestrated
blood vascular EC 22,180. VEGFR-3 is upregulated on blood vascular EC in pathologic conditions
such as vascular tumors and in the periphery of solid tumors 120,154. A recombinant soluble
extracellular portion of VEGFR-3 can disrupt the development of lymphatic vessels in animal
models by inhibiting VEGF-C and VEGF-D actions that leads to lymphatic EC apoptosis 121,181.
Transgenic mice overexpressing the extracellular portion of VEGFR-3 in the skin completely lack
dermal lymphatic vessels and also have poorly developed deeper lymphatic vessels especially
during development 181. Missense mutations in VEGFR-3 have been linked to hereditary
lymphedema in humans and also to a similar condition in a mouse model of lymphedema 182,183.
VEGFR-3 gene targeted  mice die at E9.5 from defective remodeling of the primary vascular
plexus and disturbed hematopoiesis 138.
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Other factors involved in vascular biology
Platelet derived growth factors
The platelet-derived growth factors (PDGF) belong to the VEGF/PDGF family. PDGF monomers
include PDGF-A, PDGF-B, PDGF-C and PDGF-D 184,185. Through binding their receptor tyrosine
kinases PDGFRa and PDGFRß, PDGFs act as paracrine growth factors during development and as
mitogens for fibroblasts, SMC, EC and many other cell types in the adult 185. PDGFs promote
wound healing and overexpression of PDGFs has been linked to many diseases such as
atherosclerosis, fibrotic diseases and neoplasia 186,187. Mice deficient for PDGF-B or PDGFRß die
during development or perinatally from absence of mesangial cells in the kidney, defective vascular
development, aortal dilatation, and defective PC recruitment leading to hemorrhaging (see Table 2)
139,140.
Fibroblast growth factors
The fibroblast growth factors (FGF) comprise at least 22 secreted growth factors with four tyrosine
kinase receptors and pleiotropic effects during development and adult physiology 188,189. FGFs
induce proliferation of a number of cell types: they are involved in tissue repair, vasculogenesis,
angiogenesis, hematopoiesis and tumor growth 190. FGF-1, FGF-2, FGF-4 and FGF-5 have been
shown to induce angiogenesis in vivo 188,191,192.
Angiopoietins and Tie-receptors
Angiopoietins (Ang) are involved in the formation and maintenance of the vascular system 193-195.
Ang-1 and Ang-4 activate the Tie-2-receptor and Ang-2 is a Tie-2 antagonist whereas no ligand has
been found for Tie-1 196-199. The Ang/Tie-2 system mediates vessel stabilization through EC-PC
interactions whereas the function of Tie-1 is unknown. During development, Ang-1 is involved in
vascular remodeling, maturation and stabilization and also in EC-PC interactions 141,144,195,200. Ang-2
is involved in postnatal vascular and lymphatic vessel remodeling 142. In adults, Ang-2 is
upregulated during angiogenic sprouting in the presence of VEGF and during vessel regression in
the absence of VEGF 197,201,202. Ang-2 inhibition is anti-angiogenic in a rat corneal angiogenesis
VEGFs and Bmx in the Regulation of Angiogenesis and Lymphangiogenesis 19
assay 203. An activating mutation of Tie-2 has been found in patients with venous malformations
involving dilated vessels and incomplete vessel PC coverage 204. Overexpressing Ang-1 in mouse
skin results in larger, more branched vessels resistant to leakage 205. Adenoviral transfer of Ang-1
induced angiogenic vessels resistant to vascular leakage 205. Ang-1 KO mice are embryonic lethal at
E12.5 from defective vascular remodeling (see Table 2) 141. Tie-2 gene targeted embryos die on
E9.5-E12.5 from insufficient formation of the vascular plexus, insufficient sprouting and
recruitment of perivascular cells and from myocardial developmental defects 144. A similar
phenotype of disorders in vascular maintenance is also seen in adult mice with a Tie-2 conditional
knockout that is activated 206. Tie-1 deficient mice exhibit defects in EC integrity resulting in edema
and hemorrhage and death at E13.5-P0 143. Soluble forms of the extracellular domains of Tie-1 and
Tie-2 have been described 207,208.
Ephrins and Ephs
Ephrins are membrane-bound multimeric ligands which bind to the Eph tyrosine kinase receptors
on opposing cells resulting in bi-directional signaling between cells, in the generation and
maintenance of patterns of cellular organization, especially in axonal guidance during neuronal
development 209-211. The Eph-ephrin system is also involved in communication of EC with
surrounding mesenchymal cells 212,213. Murine studies have shown that ephrin B2 is expressed
primarily on arterial endothelium while its EphB4 receptor is expressed on venous endothelium
146,147. Mice lacking ephrin B2 or its cytoplasmic domain and mice lacking EphB4 are embryonic
lethal at E10-E11 from defective remodeling of the primary vascular plexus and defective venous-
arterial remodeling (see Table 2) 146,147,214.
Neuropilins
The neuropilins, Nrp-1 and Nrp-2, have roles in immunology and neuronal development but they
are also involved in angiogenesis 215,216. Neuropilins bind class 3 semaphorins which are secreted
molecules that mediate the repulsive signals during neuronal axon guidance 217. Nrp-1 also binds
VEGF, VEGF-B and PlGF while Nrp-2 binds VEGF, VEGF-C and PlGF 215. Nrp-1 acts as a co-
receptor to enhance the function of VEGF through VEGFR-2, to form complexes with VEGFR-1
and to enhance tumor angiogenesis 218-220. Overexpression of Nrp-1 in mice leads to excessive
formation of capillaries and blood vessels and hemorrhages in addition to cardiac malformations 145.
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In chick embryos, endothelial Nrp-1 expression is mostly restricted to arteries, whereas Nrp-2
primarily marks veins, indicating a role in arterial/venous identity of EC 221. Nrp-2 is specific for
arterial and lymphatic ECs and mutated Nrp-2 induces abnormalities in the formation of small
lymphatic vessels and capillaries in mice 222. Nrp-1 gene targeted mice die at E13 from vascular
defects such as insufficient development of yolk sac vascular networks, deficient neural
vascularization and transposition of large vessels (see Table 2) 223,224. It is thought that during
vascular development, Nrp-1 is required for cardiovascular development because it regulates
VEGF165 levels 224. While Nrp-2 gene targeted mice do not have a vascular phenotype, a combined
Nrp-1 and Nrp-2 KO mouse is embryonic lethal at E8.5 resembling the VEGF and VEGFR-2 KO
phenotypes 225.
Bmx tyrosine kinase
The phosphorylation of proteins in response to extracellular signals is an important regulator of the
survival, homeostasis, proliferation, differentiation and apoptosis of most cell types 226. Protein
phosphorylation is also important in cellular communication during development and in
immunological responses. The human genome has 518 known protein kinases, 1.7% of all human
genes. Mammalian protein kinases comprise of serine-threonine kinases and at least 90 protein
tyrosine kinases (PTKs) 226. PTKs are classified according to cellular localization into non-receptor
tyrosine kinases (NRTK or cytosolic TK) and receptor tyrosine kinases (RTK) located on the cell
surface. The known 32 NRTKs and 58 RTKs are subdivided according to structure and sequence
homology into 10 and 20 subfamilies, respectively 226. Protein kinases modify substrate activity
through the transfer of the phosphate of ATP to specific tyrosine residues. Activation of PTKs
requires an enhancement of the intrinsic catalytic activity and the creation of binding sites for the
recruitment of downstream signal transduction molecules 227. On the other hand, phosphorylation of
tyrosine residues outside of the activation loop in NRTKs and RTKs can negatively regulate kinase
activity 227. Protein phosphorylation is very specific as approximately only 0.05% of protein
tyrosine kinases are phosphorylated at any given moment. Protein phosphatases are capable of
regulating protein kinase activity through removal of phosphate groups from target residues 228,229.
The 130 known protein phosphatases are also subdivided into tyrosine and serine/threonine specific
kinases. Neoplastic transformation involves inactivating mutations in tumor suppressor genes or
activating gain-of-function mutations in proto-oncogenes 230,231. Approximately 50% of PTKs have
been found to be deregulated in various human cancers through for example gain-of-function
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mutations, deletions, gene amplification or chromosomal translocations. In this respect, PTKs
represent targets for cancer therapy 232.
Tec family of tyrosine kinases
The Tec family of tyrosine kinases is the second largest family of NRTKs after the rous sarcoma
oncogene (Src) family. The mammalian Tec family comprises of Tec, Btk, Itk/Tsk/Emt, Txk/Rlk
and Bmx/Etk 233. The Tec family proteins share a characteristic domain structure with a pleckstrin
homology (PH) domain in the N-terminal part, followed by a Tec homology (TH), Src homology 3
(SH3) and SH2 domains and a C-terminal tyrosine kinase domain. Tec family members are mostly
present in hematopoietic lineages but they are also expressed on other cell types 234. The Tec
kinases are involved in signal transduction in response to growth factor receptor signaling, cytokine
receptor signaling, G-protein coupled receptor signaling, antigen-receptor signaling, death receptor
signaling and integrin-mediated signaling 235. Tec kinases are regulated by many other kinases and
Tec kinases regulate at least the phosphatidylinositol-3-kinase (PI3K), the protein kinase C and the
phospholipase C gamma pathways 236,237. Mutations in Btk gene are associated with a severe
immunological B-cell deficiency termed X-linked agammaglobulinemia in humans 238,239. Similar
yet milder immunological phenotypes can be observed in Btk KO mice and in mice with Btk
mutations 240,241. Itk KO mice have disorders in T-cell maturation and thymocyte development 242.
Mice lacking Tec or Txk do not have a clear phenotype 241,242. Loss of multiple Tec family kinases
leads to more pronounced phenotypes compared to the single-gene deficient mice in Itk/Txk and
Tec/Btk double KO mice 241,242.
The Bmx tyrosine kinase
The Bone Marrow tyrosine kinase gene in chromosome X (Bmx, also called epithelial and
endothelial tyrosine kinase or Etk) was cloned from human bone marrow 243. Bmx is expressed in
arterial endothelium, in the atrial endocardium, in hematopoietic cells and in certain EC 244-247. Bmx
is activated by VEGFR-1 and Tie-2 in vitro 247. Bmx promotes epithelial and endothelial cell
survival and proliferation by upregulating VEGF in vitro, indicating a VEGF-Bmx autoregulatory
loop 248. In vitro Bmx is expressed in EC and in prostate and breast carcinoma cells and it is
involved in integrin- and tumor necrosis factor (TNF)-induced cell migration in vitro 249-252. Also,
TNF induces transactivation between Bmx and VEGFR-2 253. Bmx directly activates the PI3K-Akt
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angiogenic signaling independent of the VEGF-induced VEGFR2-PI3K-Akt signaling pathway
indicating that Bmx may be involved in TNF-induced inflammatory angiogenesis 253. Bmx interacts
with focal adhesion kinase during integrin-mediated cell migration of normal and cancer cells in
vitro and Bmx also regulates reorganization of actin filaments in vitro 251,252,254,255. Bmx is involved
in src-mediated cellular transformation through signal transducer and activator of transcription
(STAT) transcription factors, Bmx associates with STAT and dominant-negative Bmx inhibits
cellular transformation 256-258. Bmx is a target for caspase 3 during apoptosis and following caspase
cleavage, Bmx is converted into a proapoptotic form, sensitizing prostate cancer cells to apoptosis
259. On the other hand, Bmx has been shown to protect prostate cancer cells from apoptosis in vitro
and Bmx has been shown to be necessary for androgen-independent growth and survival of prostate
cancer cells 250,260. In Bmx KO mice, there was no apparent phenotype 247.
Therapeutic aspects of angiogenesis research
The basis of anti-angiogenic therapy
Pathologists have known for a long time that most solid tumors are highly vascularized 261,262.
Tumor angiogenesis was described early on in several animal models but most notably by Ehrmann
and Greenblatt who along with others proposed the existence of “humoral substances” that are
produced by tumors and which are able to induce tumor angiogenesis 263,264. Others had shown in
animal models that experimental tumors failed to thrive in the absence of neovascularization 265,266.
Later, Folkman and Williams proposed the presence of a tumor-angiogenesis factor and Folkman
also proposed anti-angiogenesis as a therapeutic alternative in cancer 267,268. Angiogenesis in
neoplasia is thought to occur as a result of an imbalance in the pro-angiogenic and anti-angiogenic
stimuli. Correlation has been found in human tumors between tumor angiogenesis, tumor VEGF
expression, tumor vascularization and prognosis 67. The ability to induce angiogenesis is thought to
be one of the main hallmarks of human neoplasia 269. Tumor angiogenesis produces structurally
heterogeneous, leaky, tortuous vessels with incomplete PC/SMC coverage which grow and regress
according to tumor microenvironment needs 270. Tumor vessels are often mosaic vessels, in part
lined by tumor cells but it has also been suggested that blood conducting channels without EC
lining exist in certain tumors 271,272. Hypoxia is seen as one of the major driving forces of the
upregulation of VEGF and angiogenesis in the tumor microenvironment 273.
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Although nearly all traditional chemotherapeutics also have anti-angiogenic effects, drugs are being
developed with direct anti-angiogenic effects (see http://www.nci.nih.gov) 274. Targets of anti-
angiogenic therapy include the proteolytic enzymes involved in angiogenesis, the VEGF-VEGFR
system and integrin signaling pathways to name but a few. It is also possible to specifically target
angiogenic EC with toxins coupled to homing peptides 275. VEGF and tumor angiogenesis have
been successfully blocked in animal experiments with humanized blocking murine antibodies,
soluble VEGFR extracellular domains, RTK inhibitors or ribozyme/antisense molecules 276. Anti-
angiogenic therapy targeting the VEGF-VEGFR-system in human trials has proven to be more
challenging than previously thought. Side-effects and complications have involved known
biological effects of VEGF and patient responses have also varied, presumably because trials have
targeted resistant and highly advanced tumors 276.
Bevacizumab (Avastin‰, Genentech, USA) is an example of anti-angiogenic therapy based on
VEGF. It is a recombinant human monoclonal anti-VEGF antibody well tolerated in early trials.
Bevacizumab is in randomized Phase III trials in combination with traditional chemotherapeutic
agents in advanced colorectal adenocarcinoma, non-small cell lung cancer and in breast cancer 277
(see http://www.nci.nih.gov). Patients with newly diagnosed metastatic colon cancer who had not
received previous therapy and who received bevacizumab (Avastin™) along with the traditional 5-
fluoruracil, leucovorin and irinotecan (IFL) regimen had substantially longer overall survival time
(by about 5 months) than those that received only the IFL regimen. Bevacizumab is the first anti-
angiogenesis agent to prove effective in a randomized Phase III trial.
Angiogenesis in wound healing and rheumatoid arthritis
Wound healing involves the concerted action of cytokines and growth factors including VEGF as
summarized in Table 3 278. Directly after the injury, platelets and injured cells release wound
healing mediators. Polymorphonuclear (PMN) leukocytes are recruited to the site of injury
followed by macrophages to remove all necrotic and foreign material: PMN leukocytes and
especially macrophages are reservoirs of growth factors and cytokines during the healing process.
A provisional matrix is formed through deposition of fibrin, fibronectin, vitronectin and connective
tissue. In the adult, EC at the wound edge proliferate and migrate via lamellopodial crawling over
the provisional matrix. Fibroblasts and EC become the major cell populations within the wound as
the inflammation subsides and a highly vascular granulation tissue is formed 278. The granulation
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tissue matures through deposition of collagen and a decrease in vascularity. VEGF is secreted by
the platelets directly after injury, very early by keratinocytes at the wound edge, by macrophages
and also possibly by other cells in the granulation tissue 279-281. Re-epithelialization is delayed in
genetically diabetic mice with decreased baseline dermal VEGF expression 280. Wound healing is
also impaired in FGF-2 gene targeted mice partially due to decreased granulation tissue
angiogenesis 282. When chronically overexpressed in the skin of transgenic mice the anti-angiogenic
matrix molecule thrombospondin-1 delays wound healing although the anti-angiogenic vasostatin
did not affect wound healing even at anti-tumor dosage in a mouse tumor xenograft model 283,284.
Growth factor/ Cytokine Main cell source Function
FGF-1, FGF-2 Macrophages,
EC
Angiogenesis, fibroblast proliferation
Colony stimulating factor
(CSF-1)
Many cells Macrophage activation and matrix synthesis
Epidermal growth factor
(EGF)
Platelets Pleiotropic, cell motility, proliferation
Heparin binding epidermal
growth factor-like growth
factor (HB-EGF)
Macrophages Pleiotropic, cell motility, proliferation
Insulin-like growth factor-1
(IGF-1)
Fibroblasts, keratinocytes Re-epithelialization, matrix synthesis, angiogenesis
Interleukin-1a (IL-1a), IL-1b Neutrophils Pleiotropic expression of growth factors
Keratinocyte growth factor
(KGF)
Fibroblasts Keratinocyte motility and proliferation
PDGFs Platelets, macrophages,
keratinocytes
Fibroblast recruitment and proliferation, macrophage
recruitment and activation, matrix synthesis
Transforming growth factor-
a (TGF-a)
Macrophages,
keratinocytes
Pleiotropic, cell motility, proliferation
TGF-b1, TGF-b2 Platelets, macrophages Keratinocyte motility, macrophage/fibroblast
recruitment, matrix synthesis, remodeling, angiogenesis
TGF-b3 Macrophages Anti-scarring effects
Tumor necrosis factor a
(TNF-a)
Neutrophils Pleiotropic expression of growth factors
VEGF Macrophages,
keratinocytes
Angiogenesis, permeability changes
Table 3. A list of important growth factors and cytokines involved in wound healing, their main
cellular sources during wound healing and their proposed functions.
Infectious diseases and autoimmune disorders involve the recruitment of inflammatory cells which
express angiogenic molecules such as VEGF 285. Rheumatoid arthritis (RA) is an autoimmune
chronic inflammatory disorder with increased angiogenesis in the synovial membrane and in the
proliferating pannus tissue and increased expression of angiogenic peptides in the synovial
membrane and fluid 286. VEGF and VEGFRs are expressed in the synovial membrane 287,288. High
VEGF concentrations are found in RA synovial fluid and inflammatory cells and synovial fluid
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VEGF has been shown to correlate with disease activity in juvenile RA 289-291. Most anti-rheumatic
drugs also have indirect anti-angiogenic effects. Direct anti-angiogenic therapy has also been
suggested to possibly be beneficial in RA treatment 292. In RA, targeting angiogenic factors
ameliorates experimental disease and human trials are expected to follow soon 293,294.
Other human disease involving angiogenesis
Excessive ocular neovascularization contributes to visual loss in retinopathy of prematurity and
diabetic retinopathy affecting the retinal vasculature and in age-related macular degeneration
affecting primarily the choroidal vasculature. Retinal hypoxia and inappropriate secretion of
angiogenic factors like VEGF leads to inappropriate retinal neovascularization and hemorrhages 295-
297. Experimental retinal neovascularization can be inhibited with anti-angiogenic therapy 298-300.
Clinical trials are underway to treat disease involving ocular neovascularization with bevacizumab
and ranibizumab (Lucentis‰, Genentech, USA). Psoriasis is a chronic inflammatory skin disorder
characterized by keratinocyte hyperproliferation, dermal inflammation, dermal angiogenesis and
overexpression of angiogenic factors such as VEGF 301,302. Animal models have supported the role
of VEGF in psoriasis: transgenic mice with sustained overexpression of murine VEGF in the skin
have many of the classical features of psoriasis 71,303. Pathologic angiogenesis is also involved with
endometriosis, several uterine bleeding disorders and other gynecological disorders 304.
Atherosclerotic plaque progression has been associated with increased VEGF and angiogenesis 305.
Experimental atherosclerosis can be induced with VEGF and the experimental atherosclerotic
changes can be reduced with anti-angiogenic therapy 306,307. Vascular malformations also involve
angiogenesis and the first successful treatment with anti-angiogenic agents involved regression of
pulmonary hemangiomas with administration of interferon-a2a in 1989 308. Furthermore, Tie-2
mutations have been found in hereditary vascular malformations 204.
Karri Paavonen26
Endogenous stimulators of angiogenesis
Angiogenin
Ang-1
FGF-1, FGF-2
Hepatocyte growth factor (HGF)
Insulin-like growth factor -1, -2 (IGF-1, -2)
Platelet-derived endothelial cell growth factor (PD-ECGF)
PDGF-BB
PlGF
TGF-a
TNF-a
VEGF
Endogenous inhibitors of angiogenesis
Angiostatin (fragment of plasminogen)
Antithrombin III
Arrestin (fragment of type IV collagen)
Canstatin (fragment of type IV collagen)
Endostatin (fragment of type XVIII collagen)
Heparinases
Interferon-inducible protein-10 (IP-10)
Interferon-a (IFN-a), IFN-b, IFN-g
Interleukin-12 (IL-12)
Kringle 5 (fragment of apolipoprotein a)
Plasminogen activator inhibitor (PAI)
Platelet factor-4 (PF-4)
Restin (fragment of type XV collagen)
Retinoids
TGF-b
Thrombospondin-1 (TSP-1), TSP-2
Tissue inhibitors of matrix metalloproteinases (TIMPs)
Tumstatin (fragment of type IV collagen)
Vasostatin (fragment of calreticulin)
2-methoxyestradiol
Table 4. Table of known endogenous stimulators and inhibitors of angiogenesis.
Pro-angiogenic therapy
Angiogenic growth factors may also be useful in increasing collateral vessels in coronary heart
disease, other ischemic heart conditions and in critical limb ischemia and claudication or in
ameliorating diabetic neuropathy of the lower extremities 309. Trials utilizing pro-angiogenic
therapy have shown some successful endpoints 310-312. Unrelated gene therapy has however involved
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serious side-effects in human trials 313,314. In patients with critical limb ischemia and claudication,
injection of VEGF plasmid induced the growth of functional collateral vessels and reduced
morbidity due to the vascular insufficiency 315-317. Inoperable myocardial ischemia has been treated
with naked VEGF plasmid injections resulting in clinical benefit 318-320. Adenoviral gene transfer of
VEGF has also been used as a pro-angiogenic therapy in human patients with ischemic heart
disease 321. Currently therapy is being developed utilizing different viral vectors for gene delivery
of angiogenic molecules 309. Because of the side-effects of VEGF, it has been suggested that use of
a combined approach with several growth factors such as VEGF and angiopoietins or the more
arteriogenic PlGF may lead to better results 94,322,323.
Lymphangiogenic therapy
Studies in mice have provided evidence on the possibility of manipulating tumor
lymphangiogenesis and thus possibly also lymphatic metastasis in cancer 118-121. It is unclear which
subgroups of cancer patients would benefit from such therapy. Conversely, also lymphedematous
states may be treated with pro-lymphangiogenic therapy. Inadequate lymphatic vessel functioning
may be acquired or hereditary 324,325. In acquired lymphedema, the lymphatic vessels may be
destroyed as the result of infection such as recurrent cellulitis, filiriasis or following surgical or
radiation therapy induced trauma resulting in blockage of lymph flow and lymphedema 324-326.
Hereditary lymphedema disorders involve either a partial or complete absence of lymphatic vessels
and some hereditary lymphedema syndromes have been linked to missense mutations in VEGFR-3
182,327,328. In all its forms, lymphedema is a chronic disease of tissue swelling, increased risk of
infection in the affected area, dermal fibrosis, thickening of the skin and accumulation of adipose
tissue 324,325. In animal experiments, the formation of functional lymphatic vessels has been
documented in several studies and pro-lymphangiogenic therapy may be beneficial also in human
lymphedema disorders 67.
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AIMS OF THE STUDY
The goal of this work was to contribute to the knowledge of the biology of VEGFs and to elucidate
the in vivo role of the intracellular tyrosine kinase Bmx. The specific aims of the present study
were:
I. To study the chromosomal localization, genomic amplification in cancer and relation to known
human amplicons of VEGF-B and VEGF-C.
II. To study the regulation of VEGF-B and VEGF-C expression in relation to VEGF.
III. To study lymphangiogenesis and VEGFR-3 expression in vivo, particularly in wounds, using an
animal model.
IV. To study the expression of lymphangiogenic growth factors VEGF-C and VEGF-D and their
receptors in arthritis.
V. To study the function of the Bmx tyrosine kinase in vivo using mouse transgenic and gene-
targeted mice.
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MATERIALS AND METHODS
More detailed description of the materials and methods is in the original publications.
Polymerase chain reaction (PCR) and quantitative reverse transcription-PCR. (I, IV, V)
PCR was performed with appropriate primers according to standard PCR protocols. A DNA panel
of 24 interspecies somatic cell hybrids, which retained one or two human chromosomes, was used
for the chromosomal localization of VEGF-B and VEGF-C by PCR using appropriate primers.
PCR products were visualized in 1% agarose gel with UV light and ethidium bromide. For
quantitative PCR, a LightCycler PCR machine was used, amplicons were verified by sequencing
and beta-actin was used as an internal control for determining amplicon copy number.
Southern blotting (I, V)
a-32P-dCTP-labelled cDNA inserts of plasmids representing complete VEGF-B and VEGF-C
coding domains were used as probes in Southern blotting and hybridization analysis of the somatic
cell hybrid DNAs according to manufacturer’s instructions. Mouse tail DNA Southern blotting and
analysis was performed in a similar fashion with plasmids representing Bmx coding domain.
Northern blotting (II, V)
Total RNA was isolated using kits from a commercial source. Alternatively the poly(A) mRNA
fraction was isolated by binding to oligo(dT) cellulose. 5-20 mg of total RNA or mRNA was
denatured and electrophoresed through a 1.6% formaldehyde-agarose gel, the gels were transferred
to nylon membranes which were hybridized with appropriate radiolabeled fragments and visualized
on film.
Isolation and analysis of RNA from cell culture and tissues (II, IV, V)
Tissues and cell cultures were homogenized and lysed in appropriate lysis buffer. RNA was
isolated either with oligo(dt) cellulose or with commercially available kits according to
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manufacturer’s protocol. For RT-PCR mRNA was obtained from total RNA with magnetic (dt)25-
polystyrene beads and a magnetic collector. The mRNA was used to prepare primary cDNA with
(dt)12-18 primers and SuperScript enzyme followed by RNase treatment. RNAs were transferred to
a nylon membrane and analyzed by Northern blot hybridization with a-32P-dCTP-labelled cDNA
inserts of appropriate plasmids.
Fluorescent in situ hybridization (I)
For fluorescent in situ hybridization, P1 clones (obtained from a commercial source) verified by
Southern blotting to contain part of the VEGF-B and VEGF-C genes were labeled with nick
translation with biotin-11-dUTP, biotin-14-ATP or digoxigenin 11-dUTP according to standard
protocol. Peripheral blood lymphocytes were stimulated with phytohemagglutinin and treated with
5-bromodeoxyuridine at an early replicating phase to induce G-banding. Hybridization was carried
out with the labeled probes and specific hybridization signals were detected by incubating the
hybridized slides in labeled anti-deoxigenin antibodies followed by counterstaining. The signal was
detected with fluorescent markers and image analysis was performed with personal computer with
appropriate image analysis programs and basic statistical methods.
Cell culture (II)
Cells were cultured on petri dishes in the appropriate media with added growth factors or serum.
Before stimulation cells were starved overnight. Growth factors for stimulation experiments were
obtained from commercial sources. For hypoxia treatment, cells were exposed to hypoxia in an
Anaerocult A anaerobic culture jar. For mRNA half-life studies, cells were kept in low-serum
medium, transcription was blocked with actinomycin D (10mg/ml) treatment and translation was
blocked with cycloheximide (10mg/ml).
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Immunohistochemistry (III, IV, V)
For immunohistochemistry, either Tissue-Tek-embedded frozen samples or paraffin-embedded
samples were cut with a microtome into sections. Frozen sections were fixed in acetone or
methanol. For paraffin-embedded sections, tissues were fixed in paraformaldehyde or neutral
formalin, dehydrated and embedded in paraffin. Sections were then de-parafinized and rehydrated.
Antigen retrieval was performed when necessary with microwave treatment in 0.02 M sodium
citrate, trypsin digestion or commercial kit digestion followed by treatment with hydrogen peroxide
for inhibition of background peroxidase activity. Sections were blocked by incubating them with
appropriate serum or commercial blocking kit and stained with primary and secondary antibodies
obtained from our laboratory or from commercial sources as detailed in the publications.
Immunohistochemistry kits for assaying apoptosis and cell proliferation were used according to the
manufacturer's protocol. The signal was amplified with signal amplification kits, staining was
visualized with a chromophore. Negative staining controls were by omitting the primary antibodies,
by using irrelevant primary antibodies of the same isotype or by preabsorption of the primary
antibody using an excess of the immunizing antigen. Sections were counterstained in hematoxylin
when required. Immunohistochemistry results were analyzed by microscope and digital image
analysis using a personal computer and appropriate image analysis software.
Wound experiments (III, V)
Young domestic pigs were anesthetized with intravenous ketamine hydrochloride, atropine sulfate
and diazepam. Circular punch-biopsy wounds with a 6 mm diameter or incisional wounds were
made on the backs of the pigs and the wounds were allowed to heal. The pigs were sacrificed with
a lethal dose of intravenous pentobarbital and the wounds were collected. Alternatively, mice were
anesthetized with subcutaneous ketamine hydrochloride and xylazine hydrochloride. Circular
punch-biopsy wounds with a 5 mm diameter or incisional wounds were made on the backs or ears
of the mice and the wounds were allowed to heal. The mice were sacrificed with carbon monoxide
and cervical dislocation and the wounds were collected. Pain medication in the experiments was
with either diclofenac for pigs or buprenorphine for mice. Infected wounds were discarded.
Samples were snap-frozen in liquid nitrogen and embedded in Tissue-Tek or fixed in neutral
formalin or 4% paraformaldehyde, dehydrated and embedded in paraffin for immunohistochemical
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analysis. Permits for animal experiments were acquired from the Provincial State Office of
Southern Finland or from the Helsinki University Central Hospital Ethics Committee.
Generation and analysis of transgenic mice by Western blotting (V)
The cDNA encoding full-length Bmx fused to a C-terminal hemagglutinin (HA) epitope was
cloned into a human keratin-14 (K14) promoter expression cassette and injected into fertilized
FVB/NIH mouse oocytes. The progeny were genotyped using PCR of tail DNA, Southern blotting
of tail DNAs, and Bmx expression was verified by Northern blotting and by immunoprecipitation
and Western blotting using anti-Bmx antibodies. For immunoprecipitation, frozen tissue samples
were homogenized and lysed in radioimmunoprecipitation assay (RIPA) buffer supplemented with
aprotinin, leupeptin, phenylmethylsulfonyl fluoride (PMSF) and sodium vanadate.
Immunoprecipitations were carried out from equal lysate aliquots by incubation with anti-Bmx abs,
followed by incubation with protein-G-sepharose, elution into Laemmli sample buffer and
separation in 7.5% SDS-PAGE. The proteins were transferred to a nitrocellulose membrane and
detected by using anti-Bmx abs.
High-throughput gene expression array (V)
For high-throughput gene expression analysis, total RNA from skins of newborn mice was
extracted as mentioned above, treated with DNAse I and labeled according to the manufacturer’s
protocol. Murine genome microarray gene chips were hybridized with the labeled RNAs according
to the manufacturer’s protocol and results were analyzed with a personal computer and software
provided by the manufacturer.
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RESULTS AND DISCUSSION
1. Chromosomal localization of VEGF-B and VEGF-C
VEGF-B and VEGF-C presented as possible candidate genes for mutations leading to vascular
malformations or other diseases. Mutations in Tie-2, endoglin and activin are for example
associated with venous malformations and hereditary hemorrhagic telangiectasia 1 (HHT1) and
HHT2 204,329-331. Cutaneous and cerebral capillary-venous malformations are associated with the
Krev1 interaction trapped (KRIT1) 332.
The chromosomal location of VEGF-B and VEGF-C was studied using several different
overlapping techniques. Their relation to possible amplicons present in human cancer was also
studied. PCR was used to amplify VEGF-B and VEGF-C from human rodent somatic cell hybrids
containing defined sets of chromosomes. Chromosomal localization was also studied by using
fluorescent in situ hybridization (FISH) of metaphase nuclei. VEGF-C was localized to 4q34, in the
proximity of the aspartylglucosaminidase gene locus. VEGF-B localized to 11q13, near to the
cyclin D1 locus. The 11q13 region containing the genes for cyclin D1 and EMS-1 is amplified in
many human mammary and squamous cell carcinomas 333 but VEGF-B in our analysis was not
found to be a part of this amplicon in the breast cancer cell lines analyzed.
2. Regulation of expression of VEGF, VEGF-B, VEGF-C and Ang-1
The mRNA regulation of VEGF-B and VEGF-C and angiopoietin-1 was studied in relation to the
VEGF mRNA regulation. The effects of serum and different serum component growth factors such
as PDGF, EGF and TGF-ß on the mRNA expression of VEGF, VEGF-B, VEGF-C and
angiopoietin-1 were also studied. In a Northern blotting panel of tumor and normal cell lines,
VEGF-B mRNA was present in all cell lines analyzed, VEGF mRNA was present in most and
VEGF-C mRNA was present only in certain cell lines. Stimulation of serum-starved human
fibroblast cells with serum, PDGF, EGF or TGF-ß induced the expression of VEGF and VEGF-C
but not of VEGF-B. Angiopoietin-1 expression decreased upon serum stimulation or treatment with
the growth factors. While VEGF has a short half-life, VEGF-B mRNA levels were stable
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throughout the experiments and VEGF-C was found to have a half-life of 3.5 hours; this was
increased in the presence of serum.
Hypoxia is known to induce the activation of the HIF complex and to subsequently increase VEGF
protein through increased transcription but also through post-transcriptional mechanisms such as
stabilization of the VEGF mRNA 334. Previously it had also been shown that stimulation with the
tumor promoter phorbol myristate 12,13-acetate (PMA) and expression of the Ras oncoprotein
increases VEGF mRNA expression 335,336. Additionally the mutant p53 tumor suppressor had been
shown to increase VEGF expression in vitro 337. Hypoxic treatment of rat glioma cells, human and
mouse embryo fibroblasts or fibroblasts with a dominant-negative p53 tumor promoter had no
effect on levels of VEGF-B or VEGF-C mRNA. VEGF was strongly induced in all these cell lines
while Ang-1 mRNA expression was down-regulated by hypoxia. Treatment with the tumor
promoter PMA increased the steady-state mRNA levels of VEGF and VEGF-C but not of VEGF-B
while the expression of the Ras oncoprotein had no effect on mRNA levels of VEGF-B or VEGF-
C.
This study showed that VEGF, VEGF-B and VEGF-C were differentially regulated, suggesting that
they have distinct functions in normal tissues and possibly also in the tumor environment. Although
the hypoxia-regulated VEGF is thought to be an important angiogenic driving force in the growth
of certain solid tumors, the related VEGF-B or VEGF-C were not regulated by hypoxia. On the
other hand, VEGF-C was stimulated by several of the growth factors indicating that it may have a
role in processes such as angiogenesis, inflammation and tumors, where such factors are
overexpressed.
VEGF-B was constitutively expressed in many tissues and most cell lines studied. The levels of
VEGF-B did not respond to growth factor stimulation and the degradation of the VEGF-B mRNA
was very slow. VEGF-B may be needed to regulate VEGFR-1 activation in concert with VEGF and
PlGF.
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3. VEGFR-3 in wound healing and chronic inflammation
VEGFR-3 is essential for cardiovascular development 138. This receptor is expressed on all
endothelia during early embryogenesis, whereas expression in the adult is restricted to lymphatic
EC and certain fenestrated EC 22,138,180. We studied the expression of VEGFR-3 during angiogenesis
and lymphangiogenesis in vivo during wound healing granulation tissue development and chronic
inflammation of chronic wounds. The hypothesis was that VEGFR-3 may be upregulated on blood
vascular endothelium during inflammation and angiogenesis and VEGFR-3 may also provide a tool
for studying lymphangiogenesis in vivo.
Figure 3. A graph depicting the growth of blood vascular and lymphatic vessels into wound
granulation tissue during the first two weeks after wounding. See article for details.
VEGFR-3 positive lymphatic vessels, distinct from angiogenic blood vessels by
immunohistochemical analysis, sprouted into the wound granulation tissue shortly after the blood
vessels, on days 5-7 (Fig. 4). These vessels regressed completely thereafter (Fig. 3). Blood vessels
preceded lymphatic vessels, reached a maximum density on day 5 and regressed afterwards.
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Figure 4. Figure showing concurrent angiogenesis (A, blood vessel staining for PAL-E) and
lymphangiogenesis (B, lymphatic vessel staining for VEGFR-3) in wound granulation tissue. The
vessels stain red. Background staining with hematoxylin (blue).
Few blood vessels were seen in later stages of granulation tissue maturation and scar formation. In
human samples of various chronic wounds such as a decubitus wound, a diabetic ulcer and a leg
ulcer few lymphatic vessels were seen. Surprisingly, blood vascular EC stained for VEGFR-3 in
chronic wounds.
This study showed that lymphatic vessels develop concurrently with the blood vessels but with
different kinetics during granulation tissue formation. In this study porcine skin was studied
primarily because it is structurally close to human skin unlike for example murine skin.
Lymphangiogenesis may be necessary for normal wound healing. The lag before the in-growth of
lymphatic vessels into the granulation tissue may be due to the fact that the lymphangiogenic
stimulus during wound healing is through VEGF-C secretion from pre-existing blood vessel
structures and inflammatory cells that need to accumulate at the wound site. The kinetics of
lymphatic vessel growth during the resolution of wound healing suggested that lymphatic vessels
have only a transient role during normal wound healing. Strong transient wound
lymphangiogenesis may be necessary for the resolution of inflammation i.e. evacuation of
inflammatory cells, fluid, cellular debris and proteins. Lymphangiogenesis is closely associated
with angiogenesis and these two processes may have similar regulatory pathways. The relative lack
of lymphatic vessels in chronic wounds indicated also that the VEGF-C/VEGFR-3 interplay may
be disturbed during the abnormal healing process of chronic wounds and that lack of lymphatic
vessels during the healing phase may lead to impaired wound healing. Stimulation of lymphatic
vessel growth may be of benefit in the treatment of chronic wounds. The upregulation of VEGFR-3
on blood vascular EC in chronic wounds may be due to inflammatory growth factors and cytokines.
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Cytokines and growth factors of inflammation may also change the EC phenotype towards that of
fenestrated EC and VEGFR-3 could be needed in maintaining fenestrations on blood vascular EC.
4. VEGF-C and VEGF-D and their receptors in rheumatoid arthritis
VEGF-C is upregulated by cytokines and growth factors involved in inflammation 338. VEGF-C and
VEGF-D and their receptor VEGFR-3 were therefore studied in arthritis and control synovial
membranes. The hypothesis was that the lymphangiogenic growth factors are upregulated in vivo
during the inflammation involved in arthritis. The expression of VEGF-C, VEGF-D, VEGFR-2 and
VEGFR-3 was studied by RT-PCR and immunohistochemistry in synovial samples surgically
removed from patients with osteoarthritis, ankylosing spondylitis, rheumatoid arthritis or from
healthy joints sampled from surgery due to trauma.
VEGF-C staining was strong in the hypertrophic synovial lining of arthritic joints while VEGF-D
staining was weak. By RT-PCR analysis, VEGF-C was found to be more abundant than VEGF-D
in healthy and arthritic synovium. VEGF-C and VEGF-D were found to be expressed in SMC/PC
of blood vessels. VEGFR-2 was present on blood vessel endothelium and VEGFR-3 was expressed
in lymphatic EC and also in the fenestrated synovial blood vascular endothelium.
VEGF-C was strongly expressed in tissues obtained from arthritic joints. VEGF-C may have a role
in the development and maintenance of the angiogenic inflammation seen in arthritis. The function
of VEGF-C may also be different in different environments depending on the expression levels of
VEGF-C and the localization of its receptors. VEGF-C may be more angiogenic than
lymphangiogenic in the setting of chronic inflammation where VEGFR-3 is expressed also on
fenestrated blood vascular EC. This would have to be considered when possible therapeutics
targeting the VEGF-C/VEGFR-3 pathway are designed for example to treat arthritis. VEGF-D on
the other hand was little expressed in RA, indicating that although VEGF-C and VEGF-D are
structurally related proteins binding the same receptors, their biologic function is different in vivo at
least in arthritis and possibly also in inflammation. This would also have implications on therapy
aimed at affecting the growth and/or development of the lymphatic vasculature in different
diseases.
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Relatively few lymphatic vessels were seen in the healthy synovium and they appeared to decrease
during the arthritic inflammation. The lack of lymphatic vessels may actually be contributing to the
joint swelling, inflammation and accumulation of exudate in arthritis. The expression of VEGFR-3
on synovial blood vascular EC further underlined the possible role of VEGFR-3 in the maintenance
of fenestrations of blood vascular EC.
5. The Bmx tyrosine kinase in cell proliferation, migration and angiogenesis in vivo
The Bmx tyrosine kinase is expressed primarily in arterial endothelia and the Bmx gene targeted
mice have no obvious phenotype 246,247. Bmx also increases the migratory potential of cancer cells
in vitro according to several studies. The goal was to study Bmx in in vivo angiogenesis and in
cellular migration in a mouse model.
Figure 5. Bmx is expressed in the leading edge of the migrating epidermal cells of the healing
wound. The epidermal edge is migrating left-to-right over the wound bed in the day 4 KO (A,
arrow) and WT (B, arrow) mouse skin wound. Bmx expression is indicated by the blue color due to
the ß-galactosidase reporter activity in the KO mouse whereas no staining is seen in the WT mouse.
A nuclear red counterstaining was used.
In skin wounds of the Bmx gene targeted mice, Bmx was not expressed in angiogenic blood
vessels. Bmx expression was upregulated in migrating epithelial keratinocytes during the re-
epithelialization process as visualized by ß-galactosidase staining of skin wounds (Fig. 5). The
significance of Bmx in vivo in epithelial cell migration was studied. Transgenic mice expressing
Bmx under the control of the keratin 14 promoter in skin keratinocytes were generated. The mice
had strong keratinocyte hyperproliferation in the skin indicating that overexpression of Bmx
induces epidermal keratinocyte proliferation. In vivo, Bmx did not appear to affect keratinocyte
apoptosis or differentiation. The mice also exhibited accelerated wound healing due to accelerated
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epidermal migration during the wound healing. The mice also had dermal inflammation and strong
dermal angiogenesis due to upregulation of many angiogenic and chemotactic/pro-inflammatory
chemokines and cytokines in the skin (Fig 6). The gene expression changes were verified by high-
throughput gene expression analysis.
Figure 6. Large tortuous blood vessels in the skin of K14-Bmx TG mice (A) compared to vessels in
WT littermate skin (B). Black and white inverted photo to illustrate the blood vessels in a whole
mount staining for smooth muscle actin.
The study provided a proof of concept for studying intracellular tyrosine kinases in a simple
transgenic model. Bmx has long been thought to be involved in neoplastic cell migration and
proliferation on the basis of results from in vitro studies. The study provides functional in vivo data
for the first time concerning the Bmx tyrosine kinase. Since marked Bmx expression was noted in
the migrating epithelial edge of the healing wound, overexpressing Bmx in keratinocytes was a
logical step in studying the biological function of Bmx. Bmx induces hyperproliferation of the
epidermis when overexpressed in keratinocytes. Bmx overexpression also accelerates the
keratinocyte migration observed in the re-epithelialization process. These studies thus support the
previous in vitro observations.
It has previously also been shown that the Bmx TK is activated through angiogenic pathways
involving ligand-binding to VEGFR-1 and Tie-2. It has also been reported that Bmx may be
involved in TNF-mediated angiogenesis. In our experiments, Bmx overexpression in the TG mice
appeared to induce the secretion of pro-inflammatory and angiogenic molecules from
keratinocytes. No increased VEGF secretion was seen despite the tortuous dilated vessels
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reminiscent of VEGF-induced angiogenesis in the skin of the K14-Bmx mice. Several angiogenic
inflammatory cytokines were however induced very strongly. Although the strong angiogenic
effects seen in the K14-Bmx TG mice may also be secondary due to inflammation it has been
reported that Bmx is involved in TNF-mediated angiogenesis. Bmx is transactivated with VEGFR-
2 independent of VEGF/VEGFR-2 signaling resulting in TNF-induced EC migration 253. Our model
indicates that Bmx may be involved in inflammatory angiogenesis and may present a therapeutic
target in that setting.
The study also provided a model for future studies of Bmx in experimental epithelial
carcinogenesis assays. Comparing tumor responses in the skin of KO and TG mice will provide
important functional data on the role of the Bmx tyrosine kinase in vivo in tumor biology.
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CONCLUDING REMARKS
Research in the field of angiogenesis and vascular biology has provided tools for therapeutic
intervention by either inhibiting angiogenesis in diseases such as solid tumor growth or by
stimulating angiogenesis in diseases such as ischemic heart disease. Research on VEGFs has
provided basic knowledge on the complex nature of angiogenesis.
The first generation of anti-angiogenic agents are in clinical trials and pro-angiogenic therapy with
angiogenic agents has provided promising results. Anti-angiogenic therapy is a promising
therapeutic alternative or adjunct therapy in the treatment of angiogenic solid tumors. Whether this
would apply to all human tumors is unclear. It is not well known how much active angiogenesis is
involved in the survival and growth of some of the most typical neoplasias. Mammary
adenocarcinoma for example may take over five years to grow from a single neoplastic cell into a
macroscopic tumor. Anti-angiogenic therapy may be beneficial in advanced disease inducing the
“dormancy” of metastases. On the other hand, the ongoing cancer trials often involve end-stage
cancer patients with metastasized cancer that is highly resistant to other forms of therapy. Anti-
angiogenic trials may need to be conducted in smaller populations of earlier stage tumors that have
been selected on the basis of gene-expression analysis. The traditional clinical trial study design
may also not be well suited for such purposes. Medical professionals must keep in mind that anti-
angiogenic therapy may paradoxically make tumors less accessible to conventional cytostatic
agents, more resistant to radiation therapy and anti-angiogenic therapy may also have serious side-
effects. It is also not yet clear which sub-groups of cancer patients would benefit most from anti-
angiogenic therapy with minimal side-effects and long-term clinical benefits. The many questions
concerning anti-angiogenic and pro-angiogenic therapies will hopefully be answered in the years to
come.
The discovery of the VEGFR-3 and other markers with specificity for lymphatic vascular
endothelium has provided the scientific community with tools for studying the biochemical
mechanisms of lymphangiogenesis and possibly also lymphatic metastasis of tumors. VEGF-C and
VEGF-D have been shown to be lymphangiogenic in vivo and inhibiting the VEGF-C/-D-VEGFR-
3 interaction has resulted in regression of lymphatic vessels from tumors in mice. Many solid
tumors have been shown to secrete lymphangiogenic factors and this may help cancer cells to
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metastasize to local lymph nodes and to distant locations 67,339. Although intratumoral lymphatic
vessels have been documented in certain cancers, generally it is thought that there are few clinically
relevant lymphatic vessels inside tumors because of high tumor interstitial pressure 340. Anti-
lymphangiogenic therapy may be of benefit in cancer. Inhibiting tumor lymphangiogenesis may
however favor angiogenic metastasis instead. It is not known whether angiogenic metastases are
more aggressive than lymphangiogenic metastases and what differences exist between the two.
Previously it was thought that lymphatic metastasis is a passive event of tumor cells being shed and
being washed into lymphatic vessels and lymph nodes. However, it has also been proposed that
neoplastic cells metastasize to specific locations depending on the tumor cell characteristics and
local factors, the so-called “seed and soil theory” 341. Lymphangiogenic metastasis may actually be
an active event with neoplastic cells binding to lymphatic endothelium via specific interactions and
also surviving in the lymphatic circulation through active mechanisms 342,343. One of the most
important implications of studies on lymphangiogenesis in cancer are the specific interactions
between malignant cells and EC. It is important to understand why only a tiny fraction of certain
neoplastic cells are able to metastasize to regional lymph nodes and beyond.
Recent studies have also highlighted the role of tyrosine kinases and their deregulation in cancer
and studies have provided specific targets on cancer cells for therapeutic intervention with for
example tyrosine kinase inhibitors. The Bmx tyrosine kinase has been shown to be involved in
vitro in many even opposing cell functions in cancer cells such as the regulation of cell survival,
apoptosis, differentiation, migration and transformation. This study suggests that Bmx may be
involved in vivo in the proliferation and migration of cells and in inflammatory angiogenesis.
Future studies must address in detail the role of Bmx in such scenarios.
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